MEK1 and MEK2 inhibitors and cancer therapy: the long and winding road.
Nat Rev Cancer
; 15(10): 577-92, 2015 Oct.
Article
em En
| MEDLINE
| ID: mdl-26399658
ABSTRACT
The role of the ERK signalling pathway in cancer is thought to be most prominent in tumours in which mutations in the receptor tyrosine kinases RAS, BRAF, CRAF, MEK1 or MEK2 drive growth factor-independent ERK1 and ERK2 activation and thence inappropriate cell proliferation and survival. New drugs that inhibit RAF or MEK1 and MEK2 have recently been approved or are currently undergoing late-stage clinical evaluation. In this Review, we consider the ERK pathway, focusing particularly on the role of MEK1 and MEK2, the 'gatekeepers' of ERK1/2 activity. We discuss their validation as drug targets, the merits of targeting MEK1 and MEK2 versus BRAF and the mechanisms of action of different inhibitors of MEK1 and MEK2. We also consider how some of the systems-level properties (intrapathway regulatory loops and wider signalling network connections) of the ERK pathway present a challenge for the success of MEK1 and MEK2 inhibitors, discuss mechanisms of resistance to these inhibitors, and review their clinical progress.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
MAP Quinase Quinase 1
/
MAP Quinase Quinase 2
/
Inibidores de Proteínas Quinases
/
Neoplasias
Limite:
Humans
Idioma:
En
Ano de publicação:
2015
Tipo de documento:
Article